

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)
AOKI, et al.,)
Serial Number: 09/550,371) Examiner: C.M. KAM
Filed: April 14, 2000) Group Art Unit: 1646
For: METHOD FOR TREATING PAIN BY)
PERIPHERAL ADMINISTRATION)
OF A NEUROTOXIN)
Irvine, California

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicant herewith submits a one- page form PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR § 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicant makes no admission that any item listed thereupon is material to the patentability of the invention claimed in the above-entitled patent application. Further, Applicant makes no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Applicant respectfully requests that the Examiner indicate consideration of the cited reference by returning a copy of the attached form PTO-1449 with the Examiner's initials or other appropriate marks.


If any fee is required please charge Deposit Account No. 01-0885 the appropriate amount and please consider this communication a petition requesting

consideration of this supplemental IDS.

Date: September 13, 2001

Allergan, Inc.
2525 Dupont Drive, T2-TH
Irvine, CA 92612
Tel: 714 246 4026
Fax: 714-246-4249

Respectfully submitted,


Stephen Donovan
Registration Number 33,433

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. §1.10

I hereby certify that this Supplemental Information Disclosure Statement is being deposited with the United States Postal Service on **September 13, 2001** in an envelope as "Express Mail Post Office To Addressee" mailing label number EL385557033US with sufficient postage for Express Mail addressed to Assistant Commissioner for Patents, Washington, D.C., 20231.

Susan Bartholomew

Name of person mailing paper



Signature of person mailing paper

Date: September 13, 2001

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-1449

Sheet 1 of 1

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17328	SERIAL NO.: 09/550,371
APPLICANT: AOKI, ET AL.,	TITLE: METHOD FOR TREATING PAIN BY PERIPHERAL ADMINISTRATION OF A NEUROTOXIN
FILING DATE: April 14, 2000	GROUP:

UNITED STATES PATENTS

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/n)

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

EXAMINER _____

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Aoki et al.) Examiner:
U.S. Serial No.: 09/550,371)
Filed: April 14, 2000)
For: METHOD FOR TREATING)
PAIN BY PERIPHERAL)
ADMINISTRATION OF A)
NEUROTOXIN)

**SUPPLEMENTARY
INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicant provides with regard to the above-referenced patent application one copy the document listed on the attached Form PTO-1449, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56.

While this document may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that any such document is prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge Deposit Account Number 01-0885 for any fees or charges associated with the filing of this paper and any of the attached pages and to refund any overpayment to the same deposit account.

Respectfully submitted,



Stephen Donovan
Registration Number 33,433

Date: November 28, 2000

Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612
Telephone: 714 246 4026
Fax: 714 246 4249

U.S. Serial Number: 09/550,371
Filed: April 14, 2000

Docket No: 17328 (AP)

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this Supplementary Information Disclosure Statement and any additional documents set forth as being enclosed herein are being deposited with the United States Postal Service on the date shown below, with sufficient postage as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231.

Maria Zirbes

Name of Person Mailing

Date: 11.28.00

Maria Zirbes

Signature of Person Mailing

U.S. Department of Commerce, Patent and Trademark Office		PTO form 1449	Atty Docket No.	Serial No.
			17328 (AP)	09/550,371
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant(s) Aoki et al.		
(Use several sheets if necessary)				
		Filing Date October 4, 2000		Group

U.S. Patent Documents

*Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
AA	6,063,768	5/26/00	First			
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

Foreign Patent Documents

		Document	Date	Country	Class	Subclass	Translation	
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ	
AR	
AS	

Examiner Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:) Date: December 3, 2001
AOKI, et al.) Examiner: Chih-Min-Kam
Serial Number: 09/550,371) Group Art Unit: 1653
Filed: April 14, 2000)
For: METHODS FOR TREATING PAIN)
BY PERIPHERAL)
ADMINISTRATION OF A)
NEUROTOXIN)
Irvine, California

EL 385558997US

**SUPPLEMENTARY
INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Applicant provides with regard to the above-referenced patent application a copy of the document listed on the attached 1-page Supplementary Information Disclosure Citation (Form PTO-1449), which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56.

While this document may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that any such document is prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement. These documents were disclosed in an International Search Report in the foreign counterpart of the above-identified application, and the International Search Report was received less than three (3) months ago.

The Commissioner is hereby authorized to charge any fees associated with this communication, or credit any overpayment, to Deposit Account No. 01-0885.

Date: December 3, 2001

Respectfully submitted,

Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, CA 92612
Tel: 714 246 4026
Fax: 714-246-4249


Stephen Donovan
Registration Number 33,433

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. §1.10

I hereby certify that this Supplemental Information Disclosure Statement is being deposited with the United States Postal Service on **December 3, 2001** in an envelope as "Express Mail Post Office To Addressee" mailing label number EL385558997US with sufficient postage for Express Mail addressed to Assistant Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202.

Susan Bartholomew
Name of person mailing paper

Date: December 3, 2001


Signature of person mailing paper

SUPPLEMENTAL
LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17328 (BOT)	SERIAL NO.: 09/550,371
APPLICANT: AOKI, et al.	TITLE: METHOD FOR TREATING PAIN BY PERIPHERAL ADMINISTRATION OF A NEUROTOXIN
FILING DATE: APRIL 14, 2000	GROUP: 1653

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	6,113,915	9/5/00	AOKI	424		
	AB						
	AC						
	AD						
	AE						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA	WO 97/34624	9/25/97	PCT			
	BB	WO 96/33273	10/24/96	PCT			
	BC	WO 95/30431	11/16/95	PCT			

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	Guyer, B., <i>Mechanism of botulinum toxin in the relief of chronic pain</i> , Current Review of Pain, 1999, 3:427-431, XP-001031379
	CB	Carruthers, A., et al., <i>Improvement of tension-type headache when treating wrinkles with botulinum toxin A injections</i> , Headache, Oct. 1999;39:662-665, XP-001031356
	CC	Diaz, J., et al., <i>Management of post-thoracotomy pseudoangina and myofascial pain with botulinum toxin</i> , Anesthesiology, V 91, No. 3, Sep 1999, pp. 877-879, XP-001031347
	CD	Silberstein, S., et al., <i>Botulinum toxin type A as a migraine preventive treatment</i> , Headache 2000;40:445-450, XP-002182692
	CE	Gobel, H., et al., <i>Evidence-based medicine: botulinum toxin A in migraine and tension-type headache</i> , Journal of Neurology, 2001 248 Supp 1: I/34-I/38, XP-002182693

EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: DONOVAN, Stephen) Examiner:
U.S. Serial No.: 09/550,371)
Filed: April 14, 2000) Art Unit: 1646
For: METHOD FOR TREATING)
PAIN BY PERIPHERAL)
ADMINISTRATION OF A)
NEUROTOXIN) Irvine, California

**SUPPLEMENTARY
INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicant provides with regard to the above-referenced patent application one copy of each of the eight documents listed on the attached Form PTO-1449, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. Please note that the Li, Schantz and Zhou articles were originally cited by applicant at the time the application was filed; however; copies of those references were not available at that time and are therefore being submitted herein.

While these documents may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that any such document is prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees associated with this communication, or credit any overpayment, to Deposit Account No. 01-0885.

Respectfully submitted,



Stephen Donovan
Registration Number 33,433

Date: August 9, 2000

Serial No. 09/550,371

Docket No. 17328 (AP)

Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612
Telephone: 714 246 4026
Fax: 714 246 4249

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this Supplementary Information Disclosure Statement and any additional documents set forth as being enclosed herein are being deposited with the United States Postal Service on the date shown below, with sufficient postage as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231.

Mary Stickle
Name of Person Mailing

Date: August 10, 2000

Mary Stickle
Signature of Person Mailing

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17328(AP)	SERIAL NO.:	09/550,371
APPLICANT:	Aoki et al.	TITLE:	METHOD FOR TREATING PAIN BY PERIPHERAL ADMINISTRATION OF A NEUROTOXIN
FILING DATE:	04/14/2000	GROUP:	1646

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	6,063,768	5/16/00	FIRST			
	AB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/n)
	BA						
	BB						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CA	Cheng, Guang-Shing; <i>Botox, Dermabrasion Treated Facial Leiomyomas; Skin & Allergy News</i> 2000;31(3):16.
CB	First, E. et al.; <i>Painful Cervical Dystonia: Response to Treatment with Botulinum Toxin; Mov Disord</i> 1998;13(Suppl2):100.
CC	Guyer, Barry M.; <i>Mechanism of Botulinum Toxin in the Relief of Chronic Pain; Curr Rev Pain</i> 1999;3(6):427-431.
CD	Li, Yan, et al.; <i>A Single Mutation in the Recombinant Light Chain of Tetanus Toxin Abolishes Its Proteolytic Activity and Removes the Toxicity Seen after Reconstitution with Native Heavy Chain; Biochemistry</i> 1994, 33, 7014-7020.
CE	Schantz, Edward J., et al.; <i>Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine; Microbiological Reviews</i> Mar. 1992, pp. 80-99, Vol. 56, No. 1.
CF	Tarsy, Daniel, et al.; <i>Painful Cervical Dystonia: Clinical Features and Response to Treatment With Botulinum Toxin; Mov Disord</i> 1999;14(6):1043-1045.
CG	Zhou, Liqing, et al.; <i>Expression and Purification of the Light Chain of Botulinum Neurotoxin A: A Single Mutation Abolishes Its Cleavage of SNAP-25 and Neurotoxicity after Reconstitution with the Heavy Chain; Biochemistry</i> 1995, 34, 15175-15181.
CH	

EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: AOKI, et al.) Examiner:
U.S. Serial No.: Pending)
Filed: (Herewith)) Art Unit:
For: METHOD FOR TREATING PAIN BY PERIPHERAL)
ADMINISTRATION OF A NEUROTOXIN) Irvine, California


INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicant wishes to call to the attention of the Examiner the documents cited on the accompanying Form PTO-1449. No concession is made that these documents are prior art, and applicant expressly reserves the right to antedate the documents as may be appropriate. Applicant requests that each of these documents be made of record in the above-identified application.

Respectfully submitted,


Stephen Donovan
Registration Number 33,433


Date: April 14, 2000

Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612
Telephone: 714 246 4026
Fax: 714 246 4249

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this Transmittal Letter and the additional documents set forth above as being enclosed herein are being deposited with the United States Postal Service on April 14, 2000, in an envelope as "Express Mail Post Office to Addressee," mailing Label Number EL079092522US, addressed to BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, DC 20231.

STEPHEN DONOVAN
Name of person mailing paper


Signature of person mailing paper

Date: April 14, 2000

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17328(AP)	SERIAL NO.:
APPLICANT: AOKI et al.	TITLE: METHOD FOR TREATING PAIN BY PERIPHERAL ADMINISTRATION OF A NEUROTOXIN
FILING DATE: (Herewith)	GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	5,714,468	2/3/98	BINDER			
	AB	5,766,605	6/16/98	SANDERS ET AL.			
	AC	5,989,545	11/23/99	FOSTER ET AL.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA	94/15629	7/21/94	PCT			
	BB	96/33273	10/24/96	PCT			
	BC	98/07864	2/26/98	PCT			
	BD	99/17806	4/15/99	PCT			

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CA	Barwood, Shane, et al.; <i>Analgesic Effects of Botulinum Toxin A: A Randomized, Placebo-Controlled Clinical Trial</i> ; <i>Developmental Medicine & Child Neurology</i> , 2000; 42:116-121
CB	Bigalke, H., et al.; <i>Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture</i> ; <i>Brain Research</i> , 360 (1985); 318-324.
CC	Bigalke, H., et al.; <i>Tetanus Toxin and Botulinum A. Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations from Rat Brain and Spinal Cord</i> ; <i>Naunyn-Schmiedeberg's Arch. Pharmacol</i> (1981); 316:244-251.
CD	Cheshire, et al.; <i>Botulinum Toxin in the Treatment of Myofascial Pain Syndrome</i> ; <i>Pain</i> , 1994; 59(1):65-9.
CE	DiStefano, P. S., et al.; <i>Receptor Mediated Retrograde Axonal Transport of Neurotrophic Factors is Increased After Peripheral Nerve Injury</i> ; <i>Progress in Brain Research</i> (1994); Vol. 103; Chapter 4; 35-42.

EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17328(AP)	SERIAL NO.:
APPLICANT:	AOKI et al.	TITLE: METHOD FOR TREATING PAIN BY PERIPHERAL ADMINISTRATION OF A NEUROTOXIN
FILING DATE:	(Herewith)	GROUP:

OTHER ART (Continued)
(Including Author, Title, Date, Pertinent Pages, etc.)

CF	Dixon, W. J.; <i>Efficient Analysis of Experimental Observations</i> ; <u>Ann. Rev. Pharmacol. Toxicol.</u> (1980); 20:441-462.
CG	Dubuisson, D., et al.; <i>The Formalin Test: A Quantitative Study of the Analgesic Effects of Morphine, Meperidine, and Brain Stem Stimulation in Rats and Cats</i> ; <u>Pain</u> (1977); 4:161-174.
CH	Duc, C., et al.; <i>Ultrastructural Localization of SNAP-25 Within the Rat Spinal Cord and Peripheral Nervous System</i> ; <u>The Journal of Comparative Neurology</u> (1995); 356:152-163.
CI	Fauci, A.S., et al. (Editors); <u>Harrison's Principles of Internal Medicine</u> , 14 th Edition (1998); McGraw-Hill; 2064-2065.
CJ	Garner, C.G., et al.; <i>Time Course of Distant Effects of Local Injections of Botulinum Toxin; Movement Disorders</i> ; Vol. 8, No. 1; 1993.
CK	Habermann, E.; <i>Inhibition by Tetanus and Botulinum A Toxin of the Release of (³H)noradrenaline and (³H)GABA from Rat Brain Homogenate</i> ; <u>Experientia</u> 44 (1988); 224-226.
CL	Habermann, E.; <i>I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord</i> ; <u>Naunyn Schmiedeberg's Arch. Pharmacol.</u> ; 281, 47-56 (1974).
CM	Habermann, E., et al.; <i>Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release from Cultured Mouse Brain</i> ; <u>Journal of Neurochemistry</u> ; Vol. 51; No. 2 (1988); 522-527.
CN	Hagenah, R., et al.; <i>Effects of Type A Botulinum Toxin on the Cholinergic Transmission at Spinal Renshaw Cells and on the Inhibitory Action at Ia Inhibitory Interneurones</i> ; <u>Naunyn-Schmiedeberg's Arch. Pharmacol.</u> ; 299, 267-272 (1977).
CO	Halpern, J.L., et al.; <i>Neurospecific Binding, Internalization, and Retrograde Axonal Transport</i> ; Date Unknown; pp. 221-241.
CP	Johnson, E., et al.; <i>Biomedical Aspects of Botulinum Toxin</i> ; <u>J. Toxicol.-Toxin Reviews</u> ; Feb. 18, 1999; 18(1):1-15.
CQ	Jung, H. H., et al.; <i>Expression of Neurotransmitter Genes in Rat Spinal Motoneurons After Chemodenervation with Botulinum Toxin</i> ; <u>Neuroscience</u> (1997); Vol. 78, No. 2; 469-479.

EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17328(AP)	SERIAL NO.:
APPLICANT:	AOKI et al.	TITLE: METHOD FOR TREATING PAIN BY PERIPHERAL ADMINISTRATION OF A NEUROTOXIN
FILING DATE:	(Herewith)	GROUP:

OTHER ART (Continued)
(Including Author, Title, Date, Pertinent Pages, etc.)

	CR	Kim, S. H., et al.; <i>An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat</i> ; <u>Pain</u> , 50 (1992); 355-363.
	CS	Li et al.; <i>Biochemistry</i> ; 33:7014-7020 (1994).
	CT	Mochida, S., et al.; <i>Impairment of Syntaxin by Botulinum Neurotoxin C₁ or Antibodies Inhibits Acetylcholine Release but not Ca²⁺ Channel Activity</i> ; <u>Neuroscience</u> (1995); Vol. 65; No. 3; 905-915.
	CU	Naumann, et al.; <i>Botulinum Toxin Type A in the Treatment of Focal, Axillary and Palmar Hyperhidrosis and Other Hyperhidrotic Conditions</i> ; <u>European Journal of Neurology</u> , 1999; Vol. 6(suppl4):S3-S10 and S111-S115.
	CV	Nelson, P.G., et al.; <i>Mouse Spinal Cord in Cell Culture. IV. Modulation of Inhibitory Synaptic Function</i> ; <u>Journal of Neurophysiology</u> ; Vol. 40, No. 5; Sept. 1977; 1178-1187.
	CW	Osen-Sand, A., et al.; <i>Inhibition of Axonal Growth by SNAP-25 Antisense Oligonucleotides in vitro and in vivo</i> ; <u>Nature</u> ; 29 July 1993; Vol. 364; 445-448.
	CX	Pearce, L. B., et al.; <i>Pharmacologic Characterization of Botulinum Toxin for Basic Science and Medicine</i> ; <u>Toxicon</u> (1997); Vol. 35, No. 9; 1373-1412.
	CY	Ragona, et al.; <i>Management of Parotid Sialocele with Botulinum Toxin</i> ; <u>Laryngoscope</u> , 109:August 1999; p. 1344-36..
	CZ	Ransom, B.R., et al.; <i>Mouse Spinal Cord in Cell Culture. I. Morphology and Intrinsic Neuronal Electrophysiologic Properties</i> ; <u>Journal of Neurophysiology</u> ; Vol. 40, No. 5; Sept. 1977; 1132-1150.
	DA	Ransom, B.R., et al.; <i>Mouse Spinal Cord in Cell Culture. II. Synaptic Activity and Circuit Behavior</i> ; <u>Journal of Neurophysiology</u> ; Vol. 40, No. 5; Sept. 1977; 1151-1162.
	DB	Ransom, B.R., et al.; <i>Mouse Spinal Cord in Cell Culture. III. Neuronal Chemosensitivity and its Relationship to Synaptic Activity</i> ; <u>Journal of Neurophysiology</u> ; Vol. 40, No. 5; Sept. 1977; 1163-1177.
	DC	Rees, H., et al.; <i>Do Dorsal Root Reflexes Augment Peripheral Inflammation?</i> ; <u>Neuro Report</u> ; Vol. 5, No. 7; 21 March 1994; 821-824.
	DD	Sanchez-Prieto, J., et al.; <i>Botulinum Toxin A Blocks Glutamate Exocytosis from Guinea-Pig Cerebral Cortical Synaptosomes</i> ; <u>Eur. J. Biochem.</u> (1987); 165:675-681.

EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17328(AP)	SERIAL NO.:
APPLICANT:	AOKI et al.	TITLE: METHOD FOR TREATING PAIN BY PERIPHERAL ADMINISTRATION OF A NEUROTOXIN
FILING DATE:	(Herewith)	GROUP:

OTHER ART (Continued)
(Including Author, Title, Date, Pertinent Pages, etc.)

	DE	Shantz, E.J., et al.; <i>Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine</i> ; <i>Microbiol Rev</i> ; 56:80-99 (1999).
	DF	Simpson, L.; <i>Botulinum Toxin: Potent Poison, Potent Medicine</i> ; <i>Hospital Practice</i> ; April 15, 1999; 34(4):87-91.
	DG	Singh, B.R.; <i>Critical Aspects of Bacterial Protein Toxins</i> ; <i>Natural Toxins II</i> (1996); Plenum Press, New York; pp. 63-84.
	DH	Tonra, J. R., et al.; <i>Axotomy Upregulates the Anterograde Transport and Expression of Brain-Derived Neurotrophic Factor by Sensory Neurons</i> ; <i>The Journal of Neuroscience</i> ; June 1, 1998; 18(11):4374-4383.
	DI	Tsuda, M., et al.; <i>In vivo Pathway of Thermal Hyperalgesia by Intrathecal Administration of α,β-methylene ATP in Mouse Spinal Cord: Involvement of the Glutamate-NMDA Receptor System</i> ; <i>Br. J. Pharmacol</i> (1999); 127(2):449-456.
	DJ	Wiegand, H., et al.; <i>The Action of Botulinum A Neurotoxin on the Inhibition by Antidromic Stimulation of the Lumbar Monosynaptic Reflex</i> ; <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> (1977); 298:235-238.
	DK	Wiegand, H., et al.; <i>I-Labelled Botulinum A Neurotoxin: Pharmacokinetics in Cats After Intramuscular Injection</i> ; <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> ; 292, 161-165 (1976).
	DL	Williamson, L. C., et al.; <i>Clostridial Neurotoxins and Substrate Proteolysis in Intact Neurons</i> ; <i>The Journal of Biological Chemistry</i> ; Mar. 29, 1996; Vol. 271:13; 7694-7699.
	DM	Williamson, L. C., et al.; <i>Differential Effects of Tetanus Toxin on Inhibitory and Excitatory Neurotransmitter Release from Mammalian Spinal Cord Cells in Culture</i> ; <i>Journal of Neurochemistry</i> ; 1992; Vol. 59:6; 2148-2157.
	DN	Willis, W. D.; <i>Pain</i> ; <i>The Rat Nervous System</i> ; Second Edition; 1995; Academic Press, Inc.; pages 725-750.
	DO	Woolf, C. J., et al.; <i>Neuropathic Pain: Aetiology, Symptoms, Mechanisms, and Management</i> ; <i>The Lancet</i> ; June 5, 1999; Vol. 353; 1959-1964.
	DP	Yaksh, T. L., et al.; <i>Chronic Catheterization of the Spinal Subarachnoid Space</i> ; <i>Physiology & Behavior</i> (1976); Vol. 17:1031-1036.
	DQ	Zhou et al., <i>Biochemistry</i> ; 34:15175-15181 (1995).

EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Notice of References Cited		Application/Control No.	Applicant(s)/Patent Under Reexamination	
		09/550,371	AOKI ET AL.	
Examiner		Art Unit		Page 1 of 1
Chih-Min Kam		1653		

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-6,261,572	07-2001	Donovan	424/239.1
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
 Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited

Application/Contr. No.

09/550,371

Applicant(s)/Patent Under
Reexamination

AOKII I AI

Examiner

Chih-Min Kam

Art Unit

1063

Page 1 of 1

U.S. PATENT DOCUMENTS

*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	DOCUMENT SOURCE **	
							APS	OTHER
<input type="checkbox"/>	A						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	B						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	C						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	D						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	E						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	F						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	G						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	H						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	I						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	J						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	K						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	L						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	M						<input type="checkbox"/>	<input type="checkbox"/>

FOREIGN PATENT DOCUMENTS

*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS	DOCUMENT SOURCE **	
								APS	OTHER
<input type="checkbox"/>	N	WO 95/17004	Jul. 1995	US	Aoki et al.	A61K	38/16	<input type="checkbox"/>	<input checked="" type="checkbox"/>
<input type="checkbox"/>	O	WO 94/16629	Jul. 1994	US	Borodic et al.	A61K	37/02	<input type="checkbox"/>	<input checked="" type="checkbox"/>
<input type="checkbox"/>	P							<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	Q							<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	R							<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	S							<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	T							<input type="checkbox"/>	<input type="checkbox"/>

NON-PATENT DOCUMENTS

*		DOCUMENT (Including Author, Title Date, Source, and Pertinent Pages)	DOCUMENT SOURCE **	
			APS	OTHER
<input type="checkbox"/>	U		<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	V		<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	W		<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	X		<input type="checkbox"/>	<input type="checkbox"/>

*A copy of this reference is not being furnished with this Office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)

**APS encompasses any electronic search i.e. text, image, and Commercial Databases.

U.S. Patent and Trademark Office

PTO-892 (Rev. 03-98)